NDLI: IGF-IR Targeted Therapy: Past, Present and Future

Content Provider	PubMed Central
Author	Janssen, Joseph A. M. J. L. Varewijck, Aimee J.
Copyright Year	2014
Abstract	The IGF-I receptor (IGF-IR) has been studied as an anti-cancer target. However, monotherapy trials with IGF-IR targeted antibodies or with IGF-IR specific tyrosine kinase inhibitors have, overall, been very disappointing in the clinical setting. This review discusses potential reasons why IGF-I R targeted therapy fails to inhibit growth of human cancers. It has become clear that intracellular signaling pathways are highly interconnected and complex instead of being linear and simple. One of the most potent candidates for failure of IGF-IR targeted therapy is the insulin receptor isoform A (IR-A). Activation of the IR-A by insulin-like growth factor-II (IGF-II) bypasses the IGF-IR and its inhibition. Another factor may be that anti-cancer treatment may reduce IGF-IR expression. IGF-IR blocking drugs may also induce hyperglycemia and hyperinsulinemia, which may further stimulate cell growth. In addition, circulating IGF-IRs may reduce therapeutic effects of IGF-IR targeted therapy. Nevertheless, it is still possible that the IGF-IR may be a useful adjuvant or secondary target for the treatment of human cancers. Development of functional inhibitors that affect the IGF-IR and IR-A may be necessary to overcome resistance and to make IGF-IR targeted therapy successful. Drugs that modify alternative downstream effects of the IGF-IR, so called “biasing agonists,” should also be considered.
Related Links	http://dx.doi.org/10.3389/fendo.2014.00224
Starting Page	224
File Format	PDF
ISSN	16642392
e-ISSN	16642392
Journal	Frontiers in Endocrinology
Volume Number	5
Language	English
Publisher	Frontiers Media S.A.
Publisher Date	2014-12-01
Access Restriction	Open
Rights Holder	Frontiers Media S.A.
Subject Keyword	Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Endocrinology, Diabetes and Metabolism

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

IGF-IR Targeted Therapy: Past, Present and Future

Role of Insulin in the Type 2 Diabetes Therapy: Past, Present and Future

Recombinant IGF-I: Past, present and future.

Neuroendocrinology: Past, Present and Future

Thyroid hormone therapy: past, present, and future

Artificial Pancreas: Past, Present, Future

Genetic Susceptibility to Autoimmune Thyroid Disease: Past, Present, and Future

Sulfonylureas: Assets in the past, present and future

Correction to: Thyroid hormone therapy: past, present, and future

IGF-IR Targeted Therapy: Past, Present and Future

Similar Documents

IGF-IR Targeted Therapy: Past, Present and Future

Role of Insulin in the Type 2 Diabetes Therapy: Past, Present and Future

Recombinant IGF-I: Past, present and future.

Neuroendocrinology: Past, Present and Future

Thyroid hormone therapy: past, present, and future

Artificial Pancreas: Past, Present, Future

Genetic Susceptibility to Autoimmune Thyroid Disease: Past, Present, and Future

Sulfonylureas: Assets in the past, present and future

Correction to: Thyroid hormone therapy: past, present, and future

IGF-IR Targeted Therapy: Past, Present and Future